← All trials
NCT06954597
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 4, 2025
- Primary completion
- Mar 31, 2026
- Completion date
- Mar 31, 2026
- First posted
- May 1, 2025
- Last posted
- Sep 30, 2025
- Enrollment
- 15
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Topadur Pharma AGLead sponsor
- Bioskin GmbHCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.